Introduction
============

Umbilical Cord Blood transplantation (UCBT) was first reported in 1989 by Gluckman E. *et al* ^\[[@b1]\]^ and UCB is now routinely used as a source of Haematopoietic Stem Cells (HSC). The major advantage of this source is the acceptable degree of human leukocyte antigen (HLA) mismatch compared to bone marrow (BM). It is more and immediately accessible when no available BM HLA-matched donors are found ^\[[@b2]-[@b5]\]^. In addition, UCB presents less risks of transmissible viral infection than maternal blood ^\[[@b6]\]^, and stem cells it contains present self-renewal, proliferative and immune-modulatory abilities ^\[[@b7]\]^.

Furthermore, although UCB contains one log less nucleated cells than BM and Peripheral Blood (PB), UCB units are now successfully used in transplantation of patients with myeloid and lymphatic leukemia, lymphoma, myelodysplasia, aplastic anaemia, haemoglobinopathies, thalassaemia, immune deficiency, autoimmune and inherited metabolic diseases, and other diseases especially in children ^\[[@b1],[@b2]-[@b8]\]^. However, allogeneic UCBT is limited by HLA-matching and many previous reports correlated outcomes in engraftments to HLA disparity after UCBT in patients ^\[[@b3],[@b4],[@b8],[@b9]\]^.

Many other variables are influencing outcomes after UCBT in adults such as diagnosis and stage of disease, but the nucleated cell dose has been reported to be clearly associated with the engraftment and the risk of transplant-related events ^\[[@b10]\]^. To overcome this cell dose restriction, double or multiple units of UCB are used

In children and adolescents ^\[[@b11]\]^ and in adults with a reduced intensity conditioning to benefit older patients or those for which myeloablative conditioning remains too risky ^\[[@b4],[@b15]-[@b17]\]^.

As the immunologic complications of Graft Versus Host Disease (GVHD) usually offset the therapeutic benefits of unrelated BM transplants, the UCB selection criteria for unrelated transplantation were different regarding malignant and non-malignant diseases ^\[[@b11]\]^. Specific strategies and transplant programs are developed to help in finding adequate grafts quality.

With the increasing therapeutic applications of related and unrelated UCB stem cells followed by the increased demand of UCB units, international organizations, registries and biobanks are created to improve good practices in UCB collection, manipulation and storage to achieve high quality for the UCB units, and to define standardized procedures for donor search and acquisition.

*(*[[http://factwebsite.org/CordSearch.aspx?&type=CordBloodBank&country=&state=](http://factwebsite.org/CordSearch.aspx?&type=CordBloodBank&country=&state)]{.ul})

FOCUS ON CORD BLOOD TRANSPLANTATION
-----------------------------------

### Haematology disorders/Oncology

Several studies have shown that patients with acute leukemia are the most treated with UCB units in the absence of Matched-Related Donor (MRD) or Unrelated Donor (URD). After UCB HSC Transplantation (HSCT), the incidence and severity of GVHD is less than observed with BM and PB ^\[[@b1],\ [@b2],\ [@b11]\]^. This may be due to the functional immaturity of infused lymphocytes with a decreased cytotoxicity, an altered cytokine profile, a decreased HLA expression and an increased regulatory T cell ^\[[@b12],[@b19],[@b20]\]^. Other findings suggest that even if survival is similar after transplantation with MRD, URD and UCB in children with acute leukemia, occurrence of acute and chronic GVHD and relapse remain higher respectively in MRD and URD than in UCB group ^\[[@b21]\]^, while survival after transplantation with URD UCB units is similar to Matched URD from BM ^\[[@b22]\]^.

Furthermore, the outcomes of related or unrelated UCBT in children revealed the importance of the cell dose infused as a predictor of neutrophils and platelets engraftment ^\[[@b8],[@b24]\]^. In addition, the incidence of GVHD and chronic GVHD depends on the degree of HLA mismatch in both pediatric ^\[[@b2],[@b3],[@b19],[@b21],[@b23],[@b25]-[@b28]\]^ and adult patients ^\[[@b4],[@b11],[@b12],[@b14]-[@b16],[@b29]-[@b31]\]^ as indicated in [Table 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. In fact, the infusion of partially HLA-matched UCB units, neutrophils and platelets engraftment ranged from 26-32 days ([Table 1](#tbl1){ref-type="table"}) and 20-27 days ([Table 2](#tbl2){ref-type="table"}) in pediatric and adult patients, respectively. The overall survival also increased in groups with rapid neutrophils engraftment.

###### Umbilical Cord Blood Transplantation in Children with haematopoietic malignancies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                   **Number**   **Age or median**   **Degree of HLA match**    **Neutrophil engraftment median or %**   **Platelet engraftment median or %**   **Acute GVHD I-II (%)**                     **Acute GVHD III-IV (%)**   **Chronic GVHD**             **Overall survival %**
  ------------------------------- ------------ ------------------- -------------------------- ---------------------------------------- -------------------------------------- ------------------------------------------- --------------------------- ---------------------------- ------------------------
  Rocha *et al*.\                 113          5 (\<1-15)          6/6                        26 days                                  44                                     29/107 patients                             2/107 patients              5/93 surviving               46 (2-3 years)
  1990-1997 (19)                                                                                                                                                                                                                                                                   

  Wagner *et al*.\                13           2,7 (0,1-21,3)      6/6 , 1-2/6, 3/6 or more   24 (16-53)                               54 (39-130)                            16                                          11                          na                           65 at 6 months
  1994-1995 (23)                                                                                                                                                                                                                                                                   

  Dalle *et al*.\                 \            \                   6/6, 1-2/6                 28 (16-49)                               43 (18-59)                             3/36 (6 without hematopietic malignancies   11                          3/36 surviving               59 (2-3 years)
  1996-2002\                      30           7,5 (0,1-19,5)                                                                                                                                                                                                                      
  (3)                                                                                                                                                                                                                                                                              

  Rocha *et al*.\                 99           6 (2,5-10)          6/6 , 1-2/6, 3/6 or more   32 (11-56)                               81 (16-159)                            38                                          21                          5/43 patients                35
  1994-1998 (2)                                                                                                                                                                                                                                                                    

  Kutzberg *et al*\               191          7,7                                            27                                       174                                    Na                                          42                          21% at 2 years               51 (1 year)
  2008 (25)                                                                                                                                                                                                                                                                        

  Smith *et al*. 2009 (26)        21           4,2                                            95%                                      na                                     Na                                          1,2                         0,8 (relative risk 95% CI)   43 (5 years)

  Yoo KH *et al*.\                236          na                                             18                                       45                                     Na                                          41,1\                       36,10%                       47,5 (5 years)
  1996-2003 (27)                                                                                                                                                                                                          (Grade II-IV)                                            

  Kato *et al*.\                  332          5                                              89% day 90                               na                                     na                                          46                          19%                          38 (5 years)
  2011 (28)                                                                                                                                                                                                                                                                        

  Yi E.S *et al* 2005-2010 (21)   41           9,1 (0,9-18,7)                                 19                                       51                                     Na                                          24\                         9%                           na
                                                                                                                                                                                                                          (Grade II-IV)                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA : not available CI : confidence Interval

###### Umbilical Cord Blood Transplantation in Adults with haematopoietic malignancies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                  **Number**   **Age or median**   **Degree of HLA match**                            **Neutrophil engraftment median or %**   **Platelet engraftment median or %**   **Acute GVHD**\                                   **Acute GVHD III-IV (%)**       **Chronic GVHD**    **Overall survival %**
                                                                                                                                                                                                     **I-II (%)**                                                                                          
  ------------------------------ ------------ ------------------- -------------------------------------------------- ---------------------------------------- -------------------------------------- ------------------------------------------------- ------------------------------- ------------------- ------------------------
  Rocha *et al*.\                98           24,5 (15-55)        6/6, 2/6, 3/6                                      26 (14-80)                               na                                     13                                                13                              18/16 surviving     63 (2-3 years)
  1998-2002 (29)                                                                                                                                                                                                                                                                                           

  Wagner *et al*.\               65           7,4 (0,2-56,9)      6/6, 2/6, 3/6                                      23 (9-54)                                86 (29-276)                            51/63 patients                                    17                              9/59 patients       58 (1 year)
  1994-2001 (8)                                                                                                                                                                                                                                                                                            

  Langhlin *et al*.\             150          16-60               \                                                  27 (25-29)                               60 (54-71)                             In 150 patients Grades II, III, IV : 41                                           35/69               19 (2-3 years)
  1996-2001 (30)                                                  2/6                                                                                                                                                                                                                                      

  Barker *et al*. 2000-2003\     23           24 (13-53)          Double UCB trial :\                                23 (15-41)                               na                                     52                                                13                              5/23 patients       57 (1 year)
  (4)                                                             4-6/6 matched each cord and the recipient                                                                                                                                                                                                

  Ballen *et al*\                19           49 (24-63)          Double UCB trial :\                                20 (15-34)                               41 (21-55)                             53                                                5                               5/16 patients       71 (1 year)
  2003-2005 (15)                                                  4-6/6 matched to each other and to the recipient                                                                                                                                                                                         

  Brunstein *et al*.\            106          51 (17-69)          Double UCB trial :\                                12 (0-32)                                49 (0-134)                             37/110 patients (4 without hemato malignancies)   22/110                          23/110              45 (3 years)
  2001-2005 (16)                                                  4-6/6 matched to each other and to the recipient                                                                                                                                                                                         

  Takahashi *et al*. 2007 (12)   100          38 median                                                              85%                                      na                                     Na                                                52 (Grade II-IV)                71%                 70 (3 years)

  Kumar *et al*.\                173          38 median                                                              Na                                       na                                     Na                                                32 (Grade II-IV)                28%                 36 (2 years)
  2008 (31)                                                                                                                                                                                                                                                                                                

  Astuta *et al*. 2009 (13)      114          34 median                                                              Na                                       na                                     Na                                                28 (Grade II-IV)                27%                 45 (2 years)

  Brunstein *et al*. 2010 (17)   351          37 median                                                              0,5(0,42-0,6)                            na                                                                                       0,55 (0,42-0,72)(Grade II-IV)   1,36% (0,99-1,88)   0,97 (0,92-1,35)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA : not available

Non oncology
============

Most indicated use of UCB units in non haematopoietic diseases remains the primary immune deficiencies. HSCT from an HLA-matched donor was in fact shown to correct the immune system in children ^\[[@b33]\]^. As indicated in [Table 3](#tbl3){ref-type="table"}, successful and overall survival after UCBT was found to be dependent on the degree of HLA disparity ^\[[@b34]\]^. Other studies suggested that higher infused cell doses can partially reduce the impact of HLA disparity on survival ^\[[@b8]\]^.

###### Umbilical Cord Blood Transplantation in Patients with non haematopoietic malignancies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                       **Disease**                       **Number**   **Age or median**   **Neutrophil engraftment median or %**   **Chronic GVHD**             **Overall survival %**
  ----------------------------------- --------------------------------- ------------ ------------------- ---------------------------------------- ---------------------------- ------------------------
  Prasad *et al*. 2008 (32)           Inherited metabolic disorders\    159\         na                  Na                                       na                           77 (1 year)\
                                      - Hurler Syndrome\                45\                                                                                                    65 (1 year)\
                                      - Metachromatic Leukodystrophy\   15\                                                                                                    74 (1 year)\
                                      - Krabbe Diseases\                36\                                                                                                    79 (1 year)\
                                      - Sanfilipo Syndrome\             19\                                                                                                    77 (1 year)
                                      - Adrenoleukodystrophy            13                                                                                                     

  Frangaul H. *et al*1999-2003 (33)   Primary immune Deficiencies       364          0,2-7,8             58% (day 42)                             na                           63 (1 year)

  Bizzetto *et al* 2011(34)           Hereditary BM failure             64           na                  95% of R CBT\                            Acute GVHD II-IV : 2/20\     95 (3 years)\
                                                                                                         \                                        \                            \
                                                                                                         86% of UR CBT                            Chronic 11% (2 years)\       61 (3 years)
                                                                                                                                                  \                            
                                                                                                                                                  Acute GVHD II-IV : 24%\      
                                                                                                                                                  (day 100)\                   
                                                                                                                                                  Chronic GVHD 53% (2 years)   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA : not available

R CBT : Related Cord Blood Transplantation

UR : Unrelated Cord Blood Transplantation

STATE OF THE ART OF UCB BANKING: Public or Private?
---------------------------------------------------

Public banks are for non-profit and are financed by public funds. They are involved in collecting from anonymous consent donors after baby's delivery, processing and conserving UCB units in a registry for allogenic use. For inclusion in the registry, samples are screened based on volume, cell number, tissue types, health history and infectious diseases status. The units are then made available to suitably matched recipients. A great societal benefit is obtained from this UCB altruistic donation, especially for populations with ethnic minorities. Registries of these units in public banks have become a mandatory instrumental tool for haematopoietic transplantation or applications in regenerative medicine. Reports from the Bone Marrow Donors worldwide until April 2013 indicate that there were 571,318 unrelated UCB units banked from 31 countries. To date, more than 10,000 patients have received an UCB transplant worldwide.

IParallel to these public banks, an entire industry has developed. These private (for-profit) banks improve, for a fee, collection of blood samples and cryo-preservation of UCB units for a future use for the child or a related family member for related or allogeneic transplantation. While public banks use well established criteria for UCB units storage, private banks generally store all collected units, leading to a less quality parameter than in public banks ^\[[@b35]\]^.

To meet the increasing demand in therapeutic use of UCB, the number of Public UCB banks is growing. There are now nearly 142 public banks as against 134 private banks, which are actively involved around the world with more than 780,000 units ^\[[@b36]\]^.

The total number of UCB units in private banks exceeds largely the number conserved in the public ones. Conversely, the units from the former are the mostly used for transplantation. In addition, the probability for a child to be transplanted with his own cells ranges from 1:2,500 to 1:200,000 if these are not available for his family members ^\[[@b37]\]^. Indeed, more than 180 autologous UCBT has been successfully reported by private banks for non-malignant diseases (Cord Blood Registry in USA), the use of UCB units in malignant conditions being unlikely limited by the presence of pre-leukemic cells ^\[[@b38]\]^. Also, the success rates of sibling UCB transplants from a family member are well defined than of transplants from a public donor's UCB and this is more important for ethnic populations ^\[[@b39]\]^.

Many ethical debates have sparked regarding conflicting interests between private banks and the public ones and this public-private divide appears to have arisen because of the economic challenges of the UCB banks. Private banks encourage parents to store their child's UCB as a form of biological insurance for the child itself or a family members. In these companies, communication and marketing efforts are made to open up this use to a large part of population. Autologous UCB cells couldn't be used to treat genetic diseases because they carry the same genetic disease, and when required HSC are largely harvested from BM or PB ^\[[@b42],\ [@b36]\]^.

Meanwhile, the current development of public sector policies regarding stem cells manipulation and with the increasing evidence for more therapeutic use of UCB stem cells outside of transplantation (as in regenerative medicine or in immune modulation) make them attractive to the private banks ^\[[@b43],[@b44]\]^ and approaches to accommodate between public banks and personal interest in cord blood are unlikely to be achieved.

Even if private banks have developed extensive procedures for collection and storage, and benefit rapidly from advanced biotechnology, their emergence had created disagreements about the future lack of UCB units in public banks to provide treatments of some malignant diseases such as leukemia and lymphoma, and especially in health care systems democratization and ownership of human tissues. Moral questions about how to design a health care system ensuring wellbeing, commitment of generational and social fairness, social solidarity with developing these emerging tissue economies should have answers ^\[[@b45]\]^.

Hybrid banks are gaining popularity in some countries, and companies are collecting UCB units for personal use of families and at the same time other units for unrelated use (national). Many private banks now offer UCB to matched family members of a child and include them in research projects. So, the line between private and public banks is likely to be blurred. Seems to be a functional model ensuring therapeutic and economic challenges ^\[[@b43]\]^.

LEGISLATION AND BIOETHICS
-------------------------

Most experts agree that public UCB banking is the only option to obtain a suitable transplant to a vast number of people specifically for heterogeneous populations. These public banks are typically funded in part or entirely by public funds and their primary goal is the creation of an inventory of UCB units for unrelated use. They are envisaged either for solidarity and fair access to healthcare treatment purposes.

The USA and the European Union have not only regulated the therapeutic use of UCB for cell therapies and regenerative medicine, but also the banking of UCB units and the manufacture of manipulated stem cells. At the European level, cell therapy products are considered as medicinal products or as industrially produced medicinal products according to drug registration of innovative therapies system (MTI). They can also be considered as cell therapy preparations implemented in cell therapy units without the status of pharmaceutical establishment. Most of these countries have published statements on UCB and specific documents from the competent health authority, such as "l'Agence de biomédecine in France" or the FDA (Food and Drug Administration). Standards and specific international accreditations are drawn for all the process (from the collection to the distribution for transplantation). Since 2004, the main firms of biotechnology launched in applications on muscular dystrophy, bone damage, cartilage, type I diabetes, mesenchymal stem cells, diseases of the central nervous system and regulatory T cells.

There is a general consensus and a collaborative effort to establish international guidelines for better use of UCB and cell products for cell therapies. The NetCord-Fact international standard ^\[[@b46],[@b47]\]^ is now the reference for inspection and accreditation programs for standards cord blood collection, banking and release for administration.

The European Group on Ethics in Science and New Technologies has taken a position on the ethical aspects of the private cord blood banking. Even autologous or family sibling banking is unlawful in some countries, some of them (Italy and Spain) regulate transport and storage in foreign accredited private banks in Switzerland and England where public banks coexist with the private ones.

In contrast to Europe where there is a strong bias in favor of public banks ^\[[@b41],[@b42]\]^, United States is less critical of private banking despite of the negative position of some professional organizations such as the American Academy of Pediatrics (AAP) ^\[[@b48]\]^. In Australia, UCB transplantation is restricted to recognized applications and specific ethical issues are associated with the collection, storage and access ^\[[@b49]\]^. The Canadian Blood Services provide UCB units for banking and research in parallel to existing private banks ^\[[@b50]\]^

In some countries of Asia, UCB stem cell banking is permissible and all UCB banks are regulated strictly as the blood banks such as in India. In China, there is only one public bank whereas in Japan and Korea private banks are a majority ^\[[@b51]\]^. In the absence of a clear regulation to govern the status of stem cell banks, some Eastern Arab countries banks are created as agents to well-known banks outside (as Future Health, Cells4Life, Cytocare,\...). In Iran, public bank provides UCB banking since 2012 with more than 3000 units. In some other countries such as Oman and Lebanon, public and private banks co-exist and provide tissue banking ^\[[@b52]\]^. Saudi Arabia, United Arab Emirates (UAE), and Qatar have recently launched important programs for promoting medical innovations and create public funding to support bank creation and processing ^\[[@b53]\]^. Jordan, Saudi Arabia and Qatar have currently private banks and undergo general regulations for the first and religious decrees for the latter while Banks in UAE are under specific laws ^\[[@b53]\]^.

In North Africa, ministry of public health of Algeria gave permission to UCB bank in 2010 where collection and processing of UCB units were performed since 2000 ^\[[@b54]\]^. Ethical committee remains the official authority regulating all the process since collection to transplantation. Egypt has two private banks licensed to keep cord blood cells, and three other banks are waiting for license, but the practice of stem cell therapy is limited by the Ministry of health and population to only two public centers of excellence ^\[[@b55]\]^. The Tunisian UCB bank follows the guidelines by well-established national laws dealing deontological practices and ethics and is established in the Centre National de Transfusion Sanguine ^\[[@b56]\]^.

MOROCCO: The first CB bank
--------------------------

In Morocco, the first hematology department was created in Casablanca in 1980 and it is still the only public facility where adult patients can be treated for hematological diseases. Pediatric hematological disorders and cancer are treated in two other units. Some patients are treated in private clinics located in Casablanca and Rabat. The public hospitals still have limited resources and rely heavily on non-governmental organizations to take care of these patients ^\[[@b57]\]^. The number of equipped bed ward remains insufficient while therapeutic needs of stem cell transplantations are well identified in children and adult patients and matched related family donors are not usually found. Unfortunately, only two allogeneic bone marrow transplantations have been realized till now. In addition, the cost of the transplantation procedure, in case of presence of matched donors, couldn't be supported by all population in the society.

But, the biggest obstacle to implementation of a UCB bank remains the revision of the law of organ donation and clinical trial authorization. While the world highlights the scientific and therapeutic advancement of embryonic and adult stem cells, efforts of Moroccan health system promote most often allopathic treatments. This, is due, in general, to the non-commitment of Moroccan laws to the international advancements in stem cell therapy and to many other medical devises. While infrastructures are evolving with regard to national and international standards quality, and high technological equipments are available, laws regulating clinical applications in new fields are still lagging behind.

Legislation
===========

The law No. 16-98 relating to organ donation does not allow the altruistic donation, even free. However, the collection of organs from brain dead person is finally allowed for the future organ bank. It remains that the anonymous collection of UCB, considered as "surgical waste" and it is *ex-vivo* manipulation and unrelated administration are simply prohibited, even if the therapeutic need is justified (in sibling family in the case of hematological malignancies).

Ethic between the social benefit and the financial profit
=========================================================

The issues related to the creation of a stem cell bank, revealed by the feasibility study carried out by our laboratory since 2008 using a questionnaire distributed in the maternity of the Centre Hospitalier Universitaire (CHU) Ibn Rochd in Casablanca (In press) are multiples and are important.

Clinicians interested in these new therapies could more easily find stem cells or other cell products for some transplants in the absence of organ donors and an established organ bank (example type I diabetes). Areas of medical applications are multiples and concern oncology, endocrinology, kidney disease, severe burns, immunotherapy, toxicological studies, muscular dystrophy and neurodegenerative diseases. These applications can generate significant financial returns provided that adequate legislation is in place and a good financial model is identified.

The existing national ethic committees created by ministerial decree have just an advisory role and couldn't have an executive action, especially with no specific drawn rules. However, its main and first goal is to make cell therapies accessible for all the population.

RECOMMENDATIONS
---------------

Morocco should follow some guidelines and recommendations for its attractiveness and competitiveness in the field of UCB cell therapy. These recommendations focus on the legal and technical aspects of the use of stem cells or their derivatives in therapy and should be proposed in official texts.

To facilitate integration of cell therapy, several critical points should be considered:

1.  --Allow altruistic donations of UCB cells and regulating their prelevment and transport to the processing laboratory;

2.  --Allow expansion of *ex-vivo* stem cells and the production of manipulated stem cells for cell therapy;

3.  --Create the institution involved in the manipulation and conservation of the stem cells derived UCB units and derivatives, and authorize their marketing through the creation of a national UCB bank;

4.  --Promote a public bank but allow private transplant centers in the same way as the public one's to practice stem cell therapies;

5.  --Allow biomedical research with cell therapy products derived from UCB and cord matrix by conducting trials for clinical validation of new treatment protocols and authorize the use of these products in public and private institutions approved in advance by the Ministry of Health;

6.  --Authorize the export of these UCB units to international transplant centers to be used as unrelated donor transplant to our residents abroad (MRE);

7.  --Adopt a policy of pricing and reimbursement of these UCB units and derivatives to encourage public institutions to carry out treatments and projects in clinical phase.

There is also need for the creation of a group of experts which can play a role of a regulatory agency rule on requests, for authorizations of advanced UCB stem cell therapy for biomedical research implementation. This group may also give opinion on the changes in biomedical research using stem cell products, or in case of serious side-effects observed after administration of the therapeutic. Steering committees can also be created with various objectives and timelines. This committee will define and approve new clinical investigations related to national priorities in terms of public health, cost and ethics.

CONCLUSION
----------

Our prime goal is to consider the therapeutic benefit of the stem cell products and derivatives and to make stem cell therapy accessible to Moroccan people. On the other hand, many misconceptions about donation of organs or blood are floated by illiterate and ignorant people and creating doubts about what is going to be done with them. In Arabic and Muslim cultures, people are educated to make offerings of their property, money and time, but never from themselves, even if the religion does not prohibit this type of donation. So, considerable efforts have to be made to educate large numbers of people and especially parents regarding UCB use and laws by creating public awareness and strenghthening the network between authorities, professional associations, physicians, non-governmental organizations and opinion leaders.
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